According to Adil Daud this is a big deal even though we are talking 20 people. I would tend to believe a well respected Professor of Medicine when he gets excited over these results.
Adil Daud quote:
"These findings represent an advance in the field of cancer immunotherapy," said Adil Daud, MD, director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center. "Many tests examining PD-L1 levels in tumor tissue can only modestly discriminate between responders and non-responders. This analysis accurately predicts response to anti-PD-1 therapy and can be utilized in the clinic to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition."
News 
Market Data 
Discover 
